Industry
Biotechnology
Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company was formerly known as Synthetic Biologics, Inc. and changed its name to Theriva Biologics Inc. in October 2022. Theriva Biologics Inc. is headquartered in Rockville, Maryland.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
July 31, 2024 | 7:33 pm
Portfolio Pulse from Benzinga Newsdesk
July 31, 2024 | 12:27 pm
Portfolio Pulse from Benzinga Insights
June 11, 2024 | 4:31 pm
Portfolio Pulse from Benzinga Insights
June 10, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Insights
June 05, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
May 23, 2024 | 12:20 pm
Portfolio Pulse from Benzinga Newsdesk
May 23, 2024 | 12:17 pm
Portfolio Pulse from Benzinga Newsdesk
May 07, 2024 | 11:15 am
Portfolio Pulse from Benzinga Newsdesk
May 07, 2024 | 11:14 am
Portfolio Pulse from Benzinga Newsdesk
May 02, 2024 | 9:21 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.